US EditionPublished • loading... • Updated
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
- Lucid Diagnostics, a subsidiary of PAVmed Inc., announced a public offering of common stock on April 9, 2025.
- The company intends to use proceeds from the offering for working capital and other corporate needs.
- The offering involves 12,500,000 shares priced at $1.20 each, potentially generating $15 million before expenses.
- Underwriters have a 45-day option to buy 1,875,000 additional shares, less discounts; Canaccord Genuity is sole bookrunner.
- The offering, expected to close around April 11, 2025, is subject to market conditions and customary closing procedures.
Insights by Ground AI
36 Articles
36 Articles
The Berkshire Eagle+17 Reposted by 17 other sources
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of…
Coverage Details
Total News Sources36
Leaning Left2Leaning Right1Center13Last UpdatedBias Distribution81% Center
Bias Distribution
- 81% of the sources are Center
81% Center
13%
C 81%
Factuality
To view factuality data please Upgrade to Premium
